DOCSLIB.ORG

Safety of Gadobutrol in More Than 1000 Pediatric

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Safety of Gadobutrol in More Than 1000 Pediatric Pediatr Radiol DOI 10.1007/s00247-016-3599-6 ORIGINAL ARTICLE Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study Katja Glutig1 & Ravi Bhargava2 & Gabriele Hahn3 & Wolfgang Hirsch4 & Christian Kunze5 & Hans-Joachim Mentzel6 & Jürgen F. Schaefer7 & Winfried Willinek8 & Petra Palkowitsch9 & on behalf of the GARDIAN study group Received: 5 October 2015 /Revised: 1 February 2016 /Accepted: 25 February 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Objective This subanalysis of data from the GARDIAN study Background Gadobutrol is a gadolinium-based contrast evaluated the safety and use of gadobutrol in pediatric patients agent, uniquely formulated at 1.0 mmol/ml. Although there (age <18 years). is extensive safety evidence on the use of gadobutrol in adults, Materials and methods The GARDIAN study was a large few studies have addressed the safety and tolerability of gad- phase IV non-interventional prospective multicenter post- obutrol in pediatric patients. authorization safety study performed in Europe, Asia, North America and Africa. A total of 23,708 patients were included who were scheduled to undergo cranial * Katja Glutig or spinal MRI, liver or kidney MRI, or MR angiography [email protected] with gadobutrol enhancement. The primary study end- on behalf of the GARDIAN study group point was the overall incidence of adverse drug reactions (ADRs) and serious adverse events (SAEs) following 1 Children’s Center Dresden-Friedrichstadt, gadobutrol administration. Fachärztin für Radiologie und Kinderradiologie, Results The GARDIAN study included 1,142 children Überörtliche Radiologische Gemeinschaftspraxis (age <18 years) who received gadobutrol at a mean Dresden-Loschwitz, dose of 0.13 (range 0.04–0.50) mmol/kg body weight. Standort Kinderzentrum Dresden-Friedrichstadt, Friedrichstr. 32, 01067 Dresden, Germany Gadobutrol was well tolerated in these children, with low rates of ADRs (0.5%) and no SAEs, consistent with 2 Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada results in adults enrolled in the GARDIAN study. Rates of adverse events and ADRs were unrelated to pediatric 3 Pediatric Radiology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany age or gadobutrol weight-adjusted dose. There were no symptoms suggestive of nephrogenic systemic fibrosis. 4 Pediatric Radiology, University Hospital Leipzig, Leipzig, Germany Investigators rated the contrast quality of gadobutrol- enhanced images as good or excellent in 97.8% of pe- 5 Pediatric Radiology, Martin-Luther-University Hospital Halle/Wittenberg, diatric patients, similar to the main study population. Halle, Germany Conclusion Gadobutrol is very well tolerated and provides 6 Pediatric Radiology, University Hospital Jena, excellent contrast quality at the recommended weight- Jena, Germany adjusted dose in children (age <18 years), similar to the profile 7 Division of Radiology, University Hospital Tuebingen, in adults. Tuebingen, Germany 8 Radiology, University Hospital Bonn, Bonn, Germany Keywords Children . Gadobutrol . Gadolinium-based . 9 Medical & Clinical Affairs Radiology, Bayer Pharma, contrast agent Magnetic resonance imaging Magnetic Berlin, Germany resonance angiography Pediatr Radiol Introduction serious adverse events (SAEs) in this population. The contrast quality of gadobutrol was also assessed by the study Gadobutrol (Gd-DO3A-butrol, Gadovist®, Gadavist®; Bayer investigators. Pharma, Leverkusen, Germany) is a second-generation gado- linium-based contrast agent (GBCA) used to enhance tissue contrast in MRI for a range of approved indications in adults Materials and methods and children of all ages [1]. Gadobutrol recently (January 2015) received approval from the U.S. Food and Drug GARDIAN was a phase IV non-interventional prospec- Administration (FDA) for use in MRI of the central nervous tive multicenter post-authorization safety study [17]. In system in children younger than 2 years, and gadobutrol is this post-approval commitment, data were planned to be approved in many other countries, including those in the collected on at least 20,000 patients in total, including European Union (EU), for whole-body MRI in this age group at least 600 children younger than 18 years and 100 [2]. children younger than 8 years. Bayer Pharma provided Gadobutrol is an extracellular non-ionic macrocyclic para- funding for the study design, data collection, data man- magnetic contrast agent that is uniquely formulated at agement and data evaluation of the GARDIAN study 1.0 mmol/ml, i.e. twice the gadolinium concentration of other and the current study subanalysis. currently licensed GBCAs. Combined with its high relaxivity, gadobutrol provides the highest T1-shortening effect per mil- Ethical approval liliter compared with conventional GBCAs, which contributes to an increase in signal intensity [3, 4]. The more compact Local ethics committee/institutional review board approval bolus shape permitted by the higher (1 M) gadolinium con- was obtained at each study site. Prior to study enrollment each centration is associated with enhanced image quality in faster child or guardian provided written informed consent for the imaging techniques [5, 6]. The macrocyclic structure of gad- child’s data to be used for scientific purposes, consistent with obutrol provides greater stability of the chelate and reduced the ethical principles of the Declaration of Helsinki and the release of gadolinium ions compared with linear GBCAs [7]. International Conference of Harmonisation guidelines, Good Release of gadolinium ions has been associated with the de- Clinical Practice (ICH-GCP). The study additionally adhered velopment of nephrogenic systemic fibrosis (NSF) in people to guidelines of the EMA, the FDA and local laws and with impaired renal function [8, 9]. In view of these charac- regulations. teristics, gadobutrol has been placed by the American College of Radiology, European Medicines Agency (EMA), and the Participants European Society of Urogenital Radiology in the lowest risk category for development of NSF [10–12]. Between August 2010 and April 2013, boys and girls The recommended standard dose of gadobutrol for intrave- younger than 18 years who were scheduled to undergo nous injection is 0.1 mmol/kg body weight, with doses up to approved use of gadobutrol in cranial or spinal MRI, 0.3 mmol/kg body weight approved for specific indications in liver or kidney MRI, or MR angiography were recruited adults. At these doses, the efficacy and safety of gadobutrol from 272 study centers in 17 countries across Europe, have been demonstrated in numerous clinical studies in adults Asia, North America and Africa (Table 1). Gadobutrol [1, 13, 14]. By contrast, there have been few studies of gado- was administered according to usual clinical practice, butrol in pediatric patients [1, 15]. In the absence of direct with no additional diagnostic or monitoring processes evidence, strategies for use of contrast agents in the pediatric for study purposes. Children with contraindications as population [16] are typically extrapolated from adult studies. stated in the Summary of Product Characteristics for GARDIAN (Gadovist® in Routine Diagnostic MRI – Gadovist (e.g., hypersensitivity to the active substance Administration in Non-selected Patients; NCT01095081) or to any of the excipients) were excluded. Children with was a prospective large-scale multicenter non-interventional moderate or severe renal impairment (estimated glomer- study initiated at the request of the German authority, when ular filtration rate [GFR]: 30–59 or <30 ml/min/1.73 m2, the label in the EU was extended to use in pediatric patients. respectively) were scheduled for follow-up investigation The study was designed to evaluate the safety and tolerability after 3 months in accordance with routine practice, at the of gadobutrol use in approved indications in people requiring discretion of the treating physician. routine contrast-enhanced MRI [17]. The main study results from GARDIAN, excluding the pediatric data, are reported Outcome measures elsewhere [17]. The current subanalysis focuses on children (<18 years), with the primary aim to investigate the incidence Patient data (demographics, medical data, safety param- of adverse events (AEs), adverse drug reactions (ADRs) and eters, treatment signs and symptoms) were documented Pediatr Radiol Table 1 Number of pediatric patients per country (safety population) Statistical analyses Country Total number of pediatric patients (n, % by region) Descriptive analyses were performed on non-missing contin- uous (median, mean, standard deviation, maxima and minima, Asia 425 (37.2) upper and lower quartiles) and categorical data (frequency China 156 (36.7) tables). Kazakhstan & Kyrgyzstan 144 (33.9) Event rates for AEs and ADRs in children were calculated Korea 108 (25.4) as a proportion of the pediatric study population. All enrolled Taiwan 16 (3.8) subjects who were administered at least 1 dose of gadobutrol Thailand 1 (0.2) were included in the safety population. Only patients who Europe 650 (56.9) underwent an MRI/MR angiography scan were included in Bosnia & Herzegovina 28 (4.3) the efficacy population. Statistical analyses were performed Czech Republic 6 (0.9) using SAS version 9.2 (SAS Institute, Cary, NC). France 9 (1.4) Germany 465 (71.5) Greece 8 (1.2) Hungary 2 (0.3) Results Italy 17 (2.6)
Load more

Recommended publications
  • Not for Immediate Release
    Press Contact: David Pitts Argot Partners 212.600.1902 [email protected] Bracco Imaging Continues its Investment in Delivering Radiological Solutions Growing Breadth of Portfolio, Research, Education and Innovation Initiatives Highlighted at the 2011 RSNA CHICAGO, November 27, 2011 – Bracco Imaging S.p.A. – one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group – is highlighting the Company’s investment and commitment to imaging agents and radiology solutions across modalities through its growing product portfolio, as well as research, education and innovation, at the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which is being held November 27 - December 2, 2011 at Chicago’s McCormick Place, booth #4839. "Bracco remains committed to the diagnostic imaging sector, investing in imaging across modalities, including X-ray, Computed Tomography (CT), Cath Lab, Magnetic Resonance Imaging (MRI), Nuclear Medicine and Ultrasound," according to Fulvio Renoldi Bracco, head of Bracco Imaging, S.p.A. "In a difficult economic climate, where investing in the future is not top of mind, Bracco remains at the forefront. We believe that imaging agents and integrated imaging solutions are critical to support radiologists and other imaging specialists in making an effective diagnosis. Our commitment to providing the market with industry-leading products and solutions, and our partnership with the medical community, therefore remains unchanged." Fulvio Renoldi Bracco concluded: "We perceive this period in the industry, and indeed in the broader markets, as an opportunity to invest and to continue to deliver the best contrast imaging solutions to market.
    [Show full text]
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Gadolinium Based Contrast Agents
    CE Credits Available CONSIDERATIONS IN THE SELECTION OF A NEW GADOLINIUM-BASED CONTRAST AGENT SUPPLEMENT TO MAY 2014 THE JOURNAL OF PRACTICAL MEDICAL IMAGING AND MANAGEMENT Considerations in the Selection of a New Gadolinium-Based Contrast Agent Michael F. Tweedle, PhD Emanuel Kanal, MD, FACR, FISMRM Robert Muller, PhD Stefanie Spielman Professor of Radiology Professor of Radiology and Neuroradiology Department of General, Organic & The Ohio State University University of Pittsburgh Medical Center Biochemical Chemistry Columbus, OH Pittsburgh, PA University of Mons Mons, Belgium Supported by an unrestricted educational grant from © May 2014 www.appliedradiology.com SUPPLEMENT TO APPLIED RADIOLOGY n 1 Publisher Kieran Anderson Executive Editor Cristen Bolan Art and Production Barbara A. Shopiro Applied Radiology and this supplement, Considerations in the Selection of a New Gadolinium-Based Contrast Agent, are published by Anderson Publishing, Ltd. The journal does not warrant the expertise of any author in a particular field, nor is it responsible for any statements by such authors. The opinions expressed in this supplement are those of the authors. They do not imply endorsement of advertised products and do not necessarily reflect the opinions or recommendations of our sponsors or the editors and staff of Applied Radiology. Copyright © 2014 by Anderson Publishing, Ltd., 180 Glenside Avenue, Scotch Plains, NJ 07076 All rights reserved. Cover images courtesy of Howard A. Rowley, MD. Considerations in the Selection of a New Gadolinium-Based Contrast Agent Our 3 esteemed faculty summarize the similarities and differences among the gadolinium-based contrast agents (GBCAs) currently utilized for magnetic resonance imaging (MRI), with emphasis on stability and relaxivity.
    [Show full text]
  • DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su
    DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment.
    [Show full text]
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Comparison of Gadoterate Meglumine and Gadobutrol in the MRI
    LEVEL 1 EBM EXPEDITED PUBLICATION ADULT BRAIN Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study) X K.R. Maravilla, X D. San-Juan, X S.J. Kim, X G. Elizondo-Riojas, X J.R. Fink, X W. Escobar, X A. Bag, X D.R. Roberts, X J. Hao, X C. Pitrou, X A.J. Tsiouris, X E. Herskovits, and X J.B. Fiebach EBM 1 ABSTRACT BACKGROUND AND PURPOSE: Effective management of patients with brain tumors depends on accurate detection and characteriza- tion of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors. MATERIALS AND METHODS: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose ϭ 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2–14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from “poor” to “excellent.” Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site. RESULTS: For all 3 readers, images of most patients (Ͼ90%) were scored good or excellent for overall lesion visualization and character- ization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated.
    [Show full text]
  • E-Tender Document
    ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS) BHOPAL Saket Nagar, Bhopal-462020 (India) Website : www.aiimsbhopal.edu.in [email protected] E-Tendering Portal: https://www.tenderwizard.com/AIIMSBHOPAL E-Tender Document E-TENDER Id: AIIMSBPLHOSP161700509092016 Rate Contact for Supply of Contrast Media to Department of Radiodiagnosis at AIIMS Bhopal Hospital, Saket Nagar, Bhopal-462 020 (India) Notice Inviting Tender On behalf of Director, AIIMS Bhopal, Medical Superintendent invites open E-Bids in the Three Bid System (i.e. Pre-qualification Bid , Technical Bid and Financial Bid) from eligible Manufacturers/Firms/Companies/Authorized Agents/Distributors/ Dealers on line through E- procurement solution portal of AIIMS Bhopal (https://www.tenderwizard.com/AIIMSBHOPAL) on mutually agreed terms and conditions and satisfactory performance for the Supply of Contrast Media to Department of Radiodiagnosis at AIIMS Bhopal Hospital, Saket Nagar, Bhopal-462 020, India and supply of items as per the Specifications details at Annexure-I for approved valid for Two years. Further Six Months may be extended under special circumstances and on mutual agreement on same terms and conditions basis. Important: The Bidder is expected to examine all instructions, forms, terms and specifications in the bidding document. The bid should be precise, complete and in the prescribed format as per the requirement of the bid document. The bid should not be conditional. Failure to furnish all information required by the bidding document or submission of a bid not responsive to the bidding documents in every respect will be at the Bidder’s risk and may result in rejection of the bid. The Bidder shall bear all costs associated with the preparation and submission of its bid and Client will in no case be held responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.
    [Show full text]
  • Overview on the Efficacy and Safety of Gadobutrol: an MRI Contrast Agent for the CNS, Body and Vessels
    CONTRAST AGENT EVALUATION Overview on the efficacy and safety of gadobutrol: an MRI contrast agent for the CNS, body and vessels Contrast-enhanced MRI has become a mainstay of clinical imaging with unlimited applications. However, a limitation of conventional contrast agents in MRI is the insufficient signal-to-noise ratios due to relaxivity. Gadobutrol (1.0 mmol/ml), an extracellular macrocyclic contrast agent of high stability, is indicated for contrast-enhanced MRI of adults, adolescents and children 2 years of age and older. Gadobutrol offers increased T1 relaxivity, which improves MR image quality and clinical use of the technique. 1 KEYWORDS: contrast-enhanced MRA n contrast-enhanced MRI n CNS n Gadavist™ Juan E Gutierrez* , n gadobutrol n gadolinium-based contrast agent n Gadovist™ n kidney n liver Sara Koenig1 & Josy Breuer2 The use of gadolinium-based contrast agents As with other GBCAs, the paramagnetic 1University of Texas at San Antonio, (GBCAs) to improve MRI has been well qualities of the gadolinium ion shortens the Health Science Center 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, established for over 20 years [1,2]. Unenhanced T1 relaxation times of nearby water protons USA MRI of the CNS, abdomen/pelvis, breast and and results in increased signal on T -weighted 2Bayer-Schering AG, Berlin, Germany 1 *Author for correspondence: vascular system has mainly been used to dis- images improving the lesion detection (sensitiv- Tel.: +1 210 567 1978 play/demarcate focal pathologies or areas of ity), characterization (specificity) and staging. Fax: +1 210 567 6464 stenosis; however, GBCAs have improved the Besides the registered trade name (GADAVIST® [email protected] detection, characterization and visualization of Injection, USA and GADOVIST®, in the rest lesions involved in such pathologies, improving of the world, the generic name (gadobutrol) the diagnostic work-up, therapy planning and and the laboratory nomenclature (Gd-DO3A- monitoring evolution after therapeutic inter- butriol or ZK 135079) have been used in some ventions [3].
    [Show full text]
  • Hypersensitivity and Cross-Reactivity References
    60 Practitioner's Corner Funding Paramagnetic Contrast Media: Hypersensitivity and The authors declare that no funding was received for the Cross-Reactivity present study. Conflicts of Interest Moreno Escobosa MC, Cruz Granados S Allergy Unit, Hospital Torrecárdenas, Almería, Spain The authors declare that they have no conflicts of interest. J Investig Allergol Clin Immunol 2018; Vol. 28(1): 60-62 doi: 10.18176/jiaci.0210 References Key words: Gadobutrol. Gadolinium-based contrast hypersensitivity. 1. Scheurer S, Lauer I, Foetisch K, San Miguel Moncin M, Retzek Cross-reactivity between gadolinium contrast media. Gadoteridol. M, et al. Strong allergenicity of Pru av 3, the lipid transfer Paramagnetic contrast media. protein from cherry, is related to high stability against thermal Palabras clave: Gadobutrol. Hipersensibilidad a contrastes de gadolinio. processing and digestion. J Allergy Clin Immunol. 2004 Reactividad cruzada entre contrastes de gadolinio. Medios de contraste Oct;114(4):900-7. paramagnéticos. 2. Asero R, Mistrello G, Roncarolo D, Vriesc S, Gautierd MF, Ciuranae C, et al. Lipid Transfer Protein: A Pan-Allergen in Plant-Derived Foods That Is Highly Resistant to Pepsin Digestion. Int Arch Allergy Immunol. 2000;122:20-32. 3. Pastorello EA, Robino AM. Clinical role of lipid transfer Gadolinium-based contrast media have been used for proteins in food allergy. Mol Nutr Food Res. 2004;48:356-62. 25 years for contrast-enhanced magnetic resonance imaging 4. Fernández Rivas M. Food Allergy in Alergológica-2005. J (MRI) because of their safety and low rates of adverse effects Investig Allergol Clin Immunol. 2009;19:S2:37-44. (0.3%) [1]. The incidence of immediate hypersensitivity 5.
    [Show full text]